Charles River Laboratories International Inc [CRL] stock is trading at $163.02, up 0.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRL shares have gain 6.43% over the last week, with a monthly amount drifted -3.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Charles River Laboratories International Inc [NYSE: CRL] stock has seen the most recent analyst activity on January 22, 2025, when William Blair downgraded its rating to a Mkt Perform. Previously, UBS downgraded its rating to Neutral on January 17, 2025, and dropped its price target to $185. On November 18, 2024, downgrade downgraded it’s rating to Underperform but maintained its price target of $164 on the stock. CLSA upgraded its rating to a Hold but stick to its price target of $205 on November 07, 2024. CLSA initiated its recommendation with a Underperform and recommended $167 as its price target on October 23, 2024. In a note dated October 07, 2024, Evercore ISI downgraded an In-line rating on this stock and revised its target price from $225 to $190.
Charles River Laboratories International Inc [CRL] stock has fluctuated between $150.79 and $275.00 over the past year. Currently, Wall Street analysts expect the stock to reach $188.67 within the next 12 months. Charles River Laboratories International Inc [NYSE: CRL] shares were valued at $163.02 at the most recent close of the market. An investor can expect a potential return of 15.73% based on the average CRL price forecast.
Analyzing the CRL fundamentals
Charles River Laboratories International Inc [NYSE:CRL] reported sales of 4.05B for the trailing twelve months, which represents a drop of -1.08%. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.02%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is 0.0 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 161.20 points at the first support level, and at 159.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 164.95, and for the 2nd resistance point, it is at 166.87.
Ratios To Look Out For
For context, Charles River Laboratories International Inc’s Current Ratio is 1.41. As well, the Quick Ratio is 1.13, while the Cash Ratio is 0.2. Considering the valuation of this stock, the price to sales ratio is 2.06, the price to book ratio is 2.41 and price to earnings (TTM) ratio is 640.55.
Transactions by insiders
Recent insider trading involved FOSTER JAMES C, Chairman, President and CEO, that happened on Feb 20 ’25 when 6075.0 shares were purchased. Corporate Executive VP & COO, Girshick Birgit completed a deal on Feb 20 ’25 to buy 1514.0 shares. Meanwhile, EVP, Corp Strategy & Develop LaPlume Joseph W sold 4400.0 shares on Feb 20 ’25.
